NO339324B1 - Humansiert antistoff eller epitopbindende fragment derav som binder CA6 glykotopen; polynucleotid og ekspresjons vektor som koder for antistoffet eller fragmentene; cytotoksisk konjugat derav; anvendelse av konjugatet til fremstillingen av et medikament; sett derav; en in vitro fremgangsmåte for inhibering av veksten av en celle som uttrykker CA6-glykotopen og en fremgangsmåte for å detektere CA6 glykotopen. - Google Patents

Humansiert antistoff eller epitopbindende fragment derav som binder CA6 glykotopen; polynucleotid og ekspresjons vektor som koder for antistoffet eller fragmentene; cytotoksisk konjugat derav; anvendelse av konjugatet til fremstillingen av et medikament; sett derav; en in vitro fremgangsmåte for inhibering av veksten av en celle som uttrykker CA6-glykotopen og en fremgangsmåte for å detektere CA6 glykotopen. Download PDF

Info

Publication number
NO339324B1
NO339324B1 NO20060812A NO20060812A NO339324B1 NO 339324 B1 NO339324 B1 NO 339324B1 NO 20060812 A NO20060812 A NO 20060812A NO 20060812 A NO20060812 A NO 20060812A NO 339324 B1 NO339324 B1 NO 339324B1
Authority
NO
Norway
Prior art keywords
antibody
cytotoxic
carbon atoms
alkenyl
epitope
Prior art date
Application number
NO20060812A
Other languages
English (en)
Norwegian (no)
Other versions
NO20060812L (no
Inventor
Daniel J Tavares
Gillian Payne
Philip Chun
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34102763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO339324(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of NO20060812L publication Critical patent/NO20060812L/no
Publication of NO339324B1 publication Critical patent/NO339324B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
NO20060812A 2003-07-21 2006-02-20 Humansiert antistoff eller epitopbindende fragment derav som binder CA6 glykotopen; polynucleotid og ekspresjons vektor som koder for antistoffet eller fragmentene; cytotoksisk konjugat derav; anvendelse av konjugatet til fremstillingen av et medikament; sett derav; en in vitro fremgangsmåte for inhibering av veksten av en celle som uttrykker CA6-glykotopen og en fremgangsmåte for å detektere CA6 glykotopen. NO339324B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48844703P 2003-07-21 2003-07-21
PCT/US2004/023340 WO2005009369A2 (en) 2003-07-21 2004-07-21 A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Publications (2)

Publication Number Publication Date
NO20060812L NO20060812L (no) 2006-04-20
NO339324B1 true NO339324B1 (no) 2016-11-28

Family

ID=34102763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060812A NO339324B1 (no) 2003-07-21 2006-02-20 Humansiert antistoff eller epitopbindende fragment derav som binder CA6 glykotopen; polynucleotid og ekspresjons vektor som koder for antistoffet eller fragmentene; cytotoksisk konjugat derav; anvendelse av konjugatet til fremstillingen av et medikament; sett derav; en in vitro fremgangsmåte for inhibering av veksten av en celle som uttrykker CA6-glykotopen og en fremgangsmåte for å detektere CA6 glykotopen.

Country Status (26)

Country Link
US (1) US20050123549A1 (enExample)
EP (1) EP1660513B9 (enExample)
JP (5) JP2007503202A (enExample)
KR (5) KR20120059657A (enExample)
CN (3) CN103554261B (enExample)
AT (1) ATE496944T1 (enExample)
AU (1) AU2004258955C1 (enExample)
BR (1) BRPI0412879A8 (enExample)
CA (1) CA2532430C (enExample)
CR (1) CR8207A (enExample)
CY (1) CY1111938T1 (enExample)
DE (1) DE602004031239D1 (enExample)
DK (1) DK1660513T5 (enExample)
EA (1) EA014640B1 (enExample)
EC (1) ECSP066294A (enExample)
ES (1) ES2360403T3 (enExample)
HR (1) HRP20110302T1 (enExample)
IL (2) IL172982A (enExample)
MX (2) MXPA06000830A (enExample)
NO (1) NO339324B1 (enExample)
NZ (3) NZ598504A (enExample)
PL (1) PL1660513T3 (enExample)
PT (1) PT1660513E (enExample)
SI (1) SI1660513T1 (enExample)
WO (1) WO2005009369A2 (enExample)
ZA (1) ZA200600375B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US9539348B2 (en) 2000-08-18 2017-01-10 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP1651162B1 (en) * 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
AU2004224925C1 (en) * 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CN104804094A (zh) * 2005-08-22 2015-07-29 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
EA020130B9 (ru) * 2005-08-22 2014-10-30 Иммьюноджен, Инк. Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата
PT2019104E (pt) 2007-07-19 2013-12-03 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
US9011864B2 (en) * 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
PL2242772T3 (pl) * 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
US9446146B2 (en) * 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
ES2475201T3 (es) * 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
NZ588884A (en) * 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
CA2761120A1 (en) * 2009-05-06 2010-11-11 Biotest Ag Uses of immunoconjugates targeting cd138
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
UY32913A (es) 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
EP2663647A4 (en) * 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
SG194567A1 (en) 2011-04-21 2013-12-30 Seattle Genetics Inc Novel binder-drug conjugates (adcs) and their use
EP2758430A4 (en) * 2011-09-20 2015-06-03 Lilly Co Eli ANTI-C-MET ANTIBODY
US10117932B2 (en) 2011-12-08 2018-11-06 Biotest Ag Uses of immunoconjugates targeting CD138
JP2012161321A (ja) * 2012-03-30 2012-08-30 Immunogen Inc Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
JP2016515093A (ja) * 2013-02-05 2016-05-26 サノフイ 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤
SI2953977T1 (en) 2013-02-05 2018-02-28 Sanofi An immuno-contrast agent for use in antibody-drug conjugate therapy
EP4575458A3 (en) * 2013-03-15 2025-09-03 Beckman Coulter, Inc. Systems and methods for panel design in flow cytometry
MX2016001541A (es) * 2013-08-02 2016-08-18 Sanofi Sa Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos.
AU2014372833B2 (en) 2013-12-23 2019-08-22 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
BR112016020065A2 (pt) * 2014-03-12 2018-02-20 Novartis Ag sítios específicos para modificar anticorpos para fazer imunoconjugados
MA40539A (fr) 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
CR20170111A (es) 2014-09-03 2017-05-23 Immunogen Inc Derivados de benzodiazepina citotóxicos
WO2016097370A2 (en) * 2014-12-18 2016-06-23 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
SG11201710639YA (en) 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
RS65120B1 (sr) 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
AU2017380871C1 (en) 2016-12-21 2025-05-15 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
IL298414B2 (en) 2017-02-28 2024-12-01 Immunogen Inc Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
JP2025506341A (ja) * 2022-02-03 2025-03-11 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｃｄ３８結合分子及びその使用
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
EP4724100A1 (en) 2023-06-07 2026-04-15 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
IL325025A (en) 2023-06-07 2026-01-01 Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron Combination therapy with BRAF inhibitors for cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO2002016401A2 (en) * 2000-08-18 2002-02-28 East Carolina University Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3540315B2 (ja) * 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
HK1049997B (en) * 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP2005523681A (ja) * 2001-10-04 2005-08-11 イミュネックス・コーポレーション Ｕｌ１６結合タンパク質４
US20050123536A1 (en) * 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
EP1575571A4 (en) * 2002-01-02 2008-06-25 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF A TUMOR
KR20060080535A (ko) * 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO2002016401A2 (en) * 2000-08-18 2002-02-28 East Carolina University Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof

Also Published As

Publication number Publication date
DE602004031239D1 (de) 2011-03-10
WO2005009369A2 (en) 2005-02-03
JP5643619B2 (ja) 2014-12-17
AU2004258955A1 (en) 2005-02-03
EP1660513A2 (en) 2006-05-31
PT1660513E (pt) 2011-05-03
IL172982A (en) 2015-11-30
JP2007503202A (ja) 2007-02-22
JP2017123857A (ja) 2017-07-20
KR20120059657A (ko) 2012-06-08
EP1660513A4 (en) 2007-07-04
EA200600275A1 (ru) 2006-08-25
KR20150126732A (ko) 2015-11-12
HK1185891A1 (zh) 2014-02-28
CN1922199B (zh) 2013-10-30
DK1660513T3 (da) 2011-05-16
NO20060812L (no) 2006-04-20
CN103554261B (zh) 2017-03-01
ECSP066294A (es) 2006-07-28
HRP20110302T1 (hr) 2011-06-30
KR101263950B1 (ko) 2013-05-31
KR20140047739A (ko) 2014-04-22
JP6144749B2 (ja) 2017-06-07
IL242336A (en) 2017-08-31
ZA200600375B (en) 2006-12-27
JP2011092194A (ja) 2011-05-12
AU2004258955C1 (en) 2012-07-26
IL172982A0 (en) 2006-06-11
CN103145844B (zh) 2016-08-03
DK1660513T5 (da) 2011-07-18
BRPI0412879A8 (pt) 2015-12-15
HK1098160A1 (en) 2007-07-13
NZ580855A (en) 2012-03-30
EA014640B1 (ru) 2010-12-30
KR20120113811A (ko) 2012-10-15
BRPI0412879A (pt) 2006-10-03
CN103145844A (zh) 2013-06-12
WO2005009369A3 (en) 2005-06-30
ATE496944T1 (de) 2011-02-15
JP2015012861A (ja) 2015-01-22
NZ598504A (en) 2013-08-30
KR20060054331A (ko) 2006-05-22
CR8207A (es) 2008-11-12
CA2532430A1 (en) 2005-02-03
SI1660513T1 (sl) 2011-06-30
MX336469B (es) 2016-01-18
EP1660513B9 (en) 2012-04-04
NZ612796A (en) 2015-02-27
CY1111938T1 (el) 2015-11-04
EP1660513B1 (en) 2011-01-26
MXPA06000830A (es) 2006-04-18
US20050123549A1 (en) 2005-06-09
JP2016128405A (ja) 2016-07-14
JP5997727B2 (ja) 2016-09-28
CN103554261A (zh) 2014-02-05
CA2532430C (en) 2016-12-13
AU2004258955B2 (en) 2011-12-01
PL1660513T3 (pl) 2011-08-31
KR101565721B1 (ko) 2015-11-03
CN1922199A (zh) 2007-02-28
KR101672664B1 (ko) 2016-11-04
ES2360403T3 (es) 2011-06-03

Similar Documents

Publication Publication Date Title
KR101672664B1 (ko) 인간화된 항체 또는 그의 항원결정기 결합절편
US9822183B2 (en) CA6 antigen-specific cytotoxic conjugate and methods of using the same
HK1211965A1 (en) A ca6 antigen-specific cytotoxic conjugate and methods of using the same
AU2012201260B2 (en) A CA6 antigen-specific cytotoxic conjugate and methods of using the same
KR20080039917A (ko) Ｃａ6 항원-특이적인 세포독성 컨쥬게이트 및 이를사용하는 방법
JP2012161321A (ja) Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法
HK1185891B (en) A ca6 antigen-specific cytotoxic conjugate and methods of using the same
HK1194396B (en) A ca6 antigen-specific cytotoxic conjugate and methods of using the same
HK1098160B (en) A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: IMMUNOGEN, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: IMMUNOGEN, US

MM1K Lapsed by not paying the annual fees